Advancing Bayesian Methods in Clinical Trials
Explore how Bayesian statistical methods are reshaping clinical trial design. Learn how FDA support, adaptive…
CertaraMarch 9, 2026
Certara Announces 2026 Certainty Event
Certainty 2026: Explore AI-driven drug development and technological innovation at the leading biosimulation event for…
CertaraMarch 9, 2026
Navigate GxP Compliance in the Cloud with Confidence
Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…
CertaraMarch 6, 2026
Pharmacovigilance Aggregate Reporting in China
Learn best practices for China pharmacovigilance aggregate reporting, with expert support and regulatory guidance insights.
CertaraMarch 6, 2026
DIA RSIDM 2026: From Doing Digital to Being Data-Driven
JTVCdGVhbV9qdW1wX2xpc3QlNUQ= March 5, 2026 The atmosphere at this year's DIA RSIDM conference was defined by…
CertaraMarch 5, 2026
Certara Expands Simcyp® Simulator to Streamline Regulatory Submissions and Internal Efficiencies
Discover how the Simcyp Simulator’s PBPK models can streamlines drug development and reduces the number…
CertaraMarch 5, 2026
Understanding and Calculating Steady State Pharmacokinetics
Steady state pharmacokinetics can seem abstract and confusing. Read this blog to gain a better…
CertaraMarch 5, 2026
Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer
This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…
Danielle PillsburyMarch 4, 2026
